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Background: Patients with advanced non-small cell lung cancer
(NSCLC) and impaired performance status (PS  2) have limited
life expectancies and decreased tolerance for drug-induced toxici-
ties. Current treatment guidelines indicate that PS 2 patients benefit
from systemic therapy. Further refinement of treatment in these
patients requires reduction of treatment-associated toxicities while
maintaining or improving efficacy. Paclitaxel poliglumex (PPX), a
macromolecular polymer–drug conjugate of paclitaxel and poly-L-
glutamic acid, may enhance the therapeutic index of paclitaxel.
Methods: Chemotherapy-naive PS 2 patients with advanced
NSCLC randomly received single-agent PPX (175 mg/m2) or a
comparator (single-agent vinorelbine or gemcitabine). The primary
end point of this study was overall survival.
Results: Overall survival was similar between treatment arms (haz-
ard ratio [HR]  0.95; log-rank p  0.686). Median and 1-year
survival were 7.3 months and 26%, respectively, for PPX versus 6.6
months and 26% for the control arm. There was a nonsignificant
trend toward improved survival in women in the PPX arm compared
with standard single agents (HR  0.65; p  0.069). The most
frequent grade 3/4 adverse events in the treatment versus control
arm were dyspnea (13% versus 17%, respectively) and fatigue (10%
versus 9%). Grade 3/4 neutropenia and anemia were reduced in the
PPX arm (2% versus 8% and 3% versus 9%, respectively). Neurop-
athy, a taxane-specific toxicity, was more common in the PPX arm;
grade 3 neuropathy was limited to 3%.
Conclusions: Single-agent PPX, dosed at 175 mg/m2, is active and
well tolerated in PS 2 patients with advanced NSCLC. Patients on
PPX required fewer red blood cell transfusions, hematopoietic
growth factors, opioid analgesics, and clinic visits than patients
receiving gemcitabine or vinorelbine.
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Nonsmall cell lung cancer (NSCLC) is one of the mostcommon malignancies worldwide and is the leading
cause of cancer-related deaths in western countries.1–3 Of the
approximately 172,000 new cases and 164,000 lung cancer-
related deaths, an estimated 90% were due to NSCLC for the
year 2005 in the United States.4,5 Most patients present with
disease beyond the scope of surgical cure.
Performance status (PS) 2 patients have significantly
shorter survival than less symptomatic patients, and most
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chemotherapy trials exclude these patients because of reports
of increased toxicities. The median survival for single-agent
first-line therapy for PS 2 patients with advanced NSCLC
ranges from 2.4 months for paclitaxel6 to 3.5 months for
vinorelbine7 and 4.8 months for gemcitabine7 (Table 1). This
is not much different than the reported survival benefit
achieved with combination therapy, but the trade-off is a
lower incidence of toxicities.6,8–10 One study demonstrated a
survival benefit for carboplatin/paclitaxel versus paclitaxel
alone in a prospectively defined subset analysis of 99 PS 2
patients (median survival  4.7 versus 2.4 months, respec-
tively).6 In a PS 2 subset analysis of a study of gemcitabine,
vinorelbine, or a combination of the two, there was no
survival benefit for the combination (median survival  3.5
versus 4.2 months, respectively).7 Because PS 2 patients are
less tolerant of therapy and only receive limited clinical
benefit, American Society of Clinical Oncology, European,
and National Comprehensive Cancer Network guidelines and
a European expert panel suggest that single-agent therapy
with drugs having demonstrated activity is appropriate in PS
2 patients.11–13 In a phase II trial of 28 elderly patients or
treatment-naive PS 2 patients with advanced NSCLC, PPX at
a dose of 175 mg/m2 every 3 weeks yielded a median survival
of 8.1 month in a PS 0-1 population and 5.4 months in a PS
2 cohort.
Paclitaxel poliglumex (PPX) is a conjugate that links
paclitaxel to a biodegradable polymeric backbone consisting
of L-glutamic acid residues.14 PPX is water soluble and
minimally immunogenic, allowing administration by 10- to
20-minute peripheral vein infusion without routine premedi-
cation. Following infusion of PPX, plasma concentrations of
conjugated taxanes decline biphasically with a distribution
phase of approximately 48 hours, followed by a long terminal
half-life of 108 to 261.5 hours. PPX is relatively stable in
circulation; the area under the curve of unconjugated pacli-
taxel is 1 to 2% of the area under the curve of conjugated
paclitaxel. The total systemic exposure to unconjugated pac-
litaxel is similar after administration of equivalent doses of
PPX and standard paclitaxel; however, the Cmax values for
paclitaxel are significantly lower in patients treated with
PPX,15 resulting in lower observed levels of alopecia and
neutropenia when PPX is used as a single agent.
Because of the observations from the phase II trial, its
convenient administration, and the potential of decreased
toxicity, this trial, PGT304 (also known as Selected Targeted
Efficacy in Lung Cancer to Lower Adverse Reactions 4), was
conducted to determine if PPX would improve survival com-
pared with standard single-agent therapy with either gemcit-
abine or vinorelbine in chemotherapy-naive PS 2 patients
with advanced NSCLC. Secondary objectives included sur-
rogate measures of efficacy and safety.
PATIENTS AND METHODS
Patient Selection
Patients were recruited from 83 centers in 10 countries
and randomly assigned in a 1:1 ratio. Randomization was
stratified by gender, geographic location, disease stage, and
history of brain metastases. Eligible patients were PS 2 and
had histologically or cytologically confirmed diagnoses of
NSCLC that were either recurrent disease previously treated
with radiation and/or surgery or stage IIIb/IV disease suitable
for palliative treatment only. Additional inclusion criteria
were absolute neutrophil count 1500/l, platelet count
100,000/l, creatinine 1.5 times upper limit of normal
(ULN), bilirubin  ULN, and transaminases and alkaline
phosphatase 2.5 times ULN (unless liver/bone metastases
were present, in which case 5.0 times ULN was allowed).
Patients with stable or treated brain metastases were eligible.
Patients were excluded if they had had any prior systemic
chemotherapy for the treatment of lung cancer; concurrent
primary malignancies except for carcinoma in situ or non-
melanoma skin cancer;  grade 2 neuropathy; evidence of
unstable neurologic symptoms within the 4 weeks before
study randomization, or clinically significant active infec-
tions. The protocol was approved through institutional ethics
review boards, and all patients provided written informed
consent.
Treatment Plan
Patients were randomized to receive either PPX or
comparator drug (investigator’s choice of gemcitabine or
vinorelbine). Each site chose the comparator and used the
drug for all patients treated. PPX (175 mg/m2) was adminis-
tered on day 1 of each 21-day cycle. At study initiation, the
dose of PPX was 235 mg/m2. The data monitoring committee
noted an increased incidence of deaths resulting from neu-
tropenia in patients treated with 235 mg/m2 PPX after 96
patients had been treated. As a result of these observations,
the dose was reduced to 175 mg/m2 PPX. Randomization
continued such that there was a 1:1 ratio between the PPX at
175 mg/m2 arm and the comparator arm.
Gemcitabine (1000 mg/m2) was administered on days
1, 8, and 15 of each 28-day cycle. Vinorelbine (30 mg/m2)
was administered on days 1, 8, and 15 of each 21-day cycle.
Patients were treated for up to 6 cycles. Patients were
not retreated until significant toxicities had resolved to
 grade 1. Retreatment could be delayed for up to 2 weeks.
The PPX dose was reduced if any of the following were
observed: febrile neutropenia; grade 4 neutropenia lasting7
days; absolute neutrophil count 1500/l at the assessment
TABLE 1. Outcome of PPX and Comparators Used in PS 2
Patients: Trial Results Compared with Historical Results
Reference Drug N
Median
Survival, mo
1-yr
Survival
Lilenbaum et al.6 Paclitaxel 50 2.4 10%
Perrone et al.7 Vinorelbine 45 3.5 20%
Perrone et al.7 Gemcitabine 41 4.2 18%
Neubauer et al.18 Gemcitabine 42 4.8 20%
Kosmidis et al.19 Gemcitabine 47 4.8 18%
Current study Vinorelbine 32 6.1 7%
Current study Gemcitabine 155 6.7 29%
Current study PPX 191 7.3 26%
PPX indicates paclitaxel poliglumex; PS, performance status.
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before dosing; grade 2 neuropathy at the time of dosing; or
any drug-related grade 3/4 nonhematologic toxicities except
manageable nausea, vomiting, hypersensitivity reactions, and
fatigue (persistent grade 3/4 nausea or vomiting uncontrolled
by medication required dose reduction). Two dose reductions
were allowed. Treatment was discontinued for patients with
persistent peripheral neuropathy  grade 3, grade 3 hyper-
sensitivity reactions despite adequate prophylaxis, and grade
4 hypersensitivity reactions.
Doses for gemcitabine and vinorelbine were adjusted
according to the respective package inserts.
Patients were withdrawn for disease progression, intol-
erable toxicity, patient withdrawal of consent, or investigator
decision to withdraw the patient.
Assessments
Evaluations at baseline, before each cycle, and at the
end of treatment included medical history, physical exami-
nation, assessment of PS, electrocardiogram, tumor status,
laboratory evaluations, and Functional Assessment of Cancer
Therapy Lung Cancer Subscale (FACT-LCS).
Hematology was assessed 8 days after PPX adminis-
tration and before each administration of comparator drug.
Hematologic adverse events were recorded from laboratory
events. All other toxicities were tabulated from investigator-
reported adverse events.
Computed tomography (CT) scans were assessed in the
last week of every second study cycle (every 6 weeks for PPX
and vinorelbine and every 8 weeks for gemcitabine). Efficacy
was assessed by the investigator; no central reviews of
images were performed. In patients who ended study treat-
ment with stable disease, partial response, or complete re-
sponse, CT scans were to be obtained every 8 weeks until
documentation of the first occurrence of one of the following:
disease progression, date of first nonstudy treatment for
NSCLC, or death. After the end of study treatment, patients
were followed to obtain the dates of disease progression,
initiation of subsequent treatment regimens, and death.
Statistical Analysis
The original sample size was 370 patients (185 per
treatment arm). Before the dose was reduced for the PPX
arm, approximately 91 patients had been randomized to the
comparator arm based on a 1:1 allocation over an accrual
period of 12 months. To maintain the original number of
patients in each final treatment arm (175 mg/m2 PPX and
comparator) after the PPX dose reduction, the randomization
ratio was adjusted to 2:1 (175 mg/m2 PPX to comparator). An
unstratified log-rank test of overall survival showed similar
survival in patients randomized to the comparator arm before
and after the dose reduction; therefore, these patients were
grouped together for the analysis. A survival analysis of
patients randomized to the comparator arm after the dose
reduction and patients who received the reduced dose of
CT-2103 yielded similar survival results as the analysis
including all patients randomized to the comparator arm [p
0.939, hazard ratio (HR)  1.01].
With the assumption that a 1.5-month median survival
difference between the 2 treatment arms was of clinical
significance, an additional 279 patients (185 randomized to
PPX and 94 randomized to the comparator) were accrued
over 6 months (with 9 months follow-up), together with the
91 patients already randomized to the comparator arm. This
number of patients would result in 80% power to detect a HR
of 1.375.
The unstratified log-rank test without adjustments for
covariates was used in the primary evaluation of survival
differences between the PPX arm (patients dosed at 175
mg/m2) and the comparator arm using a two-sided   0.05
test. All randomized patients were included in this analysis.
Additional secondary analyses were performed using the Cox
regression techniques with covariates determined to be clin-
ically meaningful to the survival of patients with NSCLC.
The fraction retention method described by Roth-
mann16 was used to evaluate whether PPX maintains 50% of
the effect of the control drugs. Because there is limited
historical data available comparing gemcitabine or vinorel-
bine with best supportive care in PS 2 NSCLC patients, the
log of the relative HR observed in the current trial was used
in the calculation.
Disease response was assessed according to response
evaluation criteria in solid tumors.17 The comparison was
made by randomized treatment group using the Fisher exact
test. Disease control was defined as the percentage of patients
alive without documented disease progression for12 weeks
after randomization. All randomized patients were included.
The comparison was made by randomized treatment group
using the Fisher exact test. The analysis of time to progres-
sion (TTP) was made using an unstratified log-rank test.
Toxicities were evaluated at each patient visit using the
National Cancer Institute Common Toxicity Criteria, version
2. All patients who received any amount of study drug were
included in the safety analyses.
Disease-related symptoms were measured by the
FACT-LCS, a validated, 5-point Likert-type scale ranging
from 0 (not at all) to 4 (very much). The total LCS score
ranged from 0 to 28, with higher scores indicative of fewer
symptoms. The Fisher exact test for equal proportions of
patients achieving at least a 2-point increase in FACT-LCS
score from baseline to week 3 was performed in the overall
sample and by each baseline covariate strata. Patients with
missing FACT-LCS scores at week 3 were classified as
having less than a 2-point increase in the primary analysis
data but classified as missing and excluded from the supple-
mental analysis.
RESULTS
A total of 477 patients were enrolled from December
2002 to June 2004: 199 were randomized to the comparator
arm, 190 were randomized to the PPX arm at the dose of 175
mg/m2, and 96 were randomized to the PPX arm at the dose
of 235 mg/m2. In the comparator arm, 32 patients received
vinorelbine and 155 received gemcitabine. The analysis pre-
sented here includes only the PPX 175 mg/m2 and compar-
ator arms. Baseline characteristics were generally well
matched between treatment arms (Table 2).
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Extent of Exposure
The median number of cycles administered was 4 in the
PPX arm compared with a median of 3.5 in the control arm.
The total number of cycles administered was 754 in the PPX
arm and 652 in the comparator arm. More patients received 6
cycles of treatment in the PPX arm than in the comparator
arm (38% versus 23%; p  0.002). The most frequent reason
for not completing all 6 cycles was progressive disease (55
and 59% in the experimental and comparator arms, respec-
tively). An additional 12% of patients in the PPX arm and
17% of patients in the comparator arm discontinued therapy
due to adverse events.
Efficacy
Survival, TTP, and response rates were similar in both
arms (Table 3). Survival was similar between treatment arms
(HR  0.95; p  0.686; Figure 1). The median overall
survival was 7.3 months in the PPX arm and 6.6 months in
the control arm. The estimated 1-year survival rate was the
same in both arms (26%). The estimated 2-year survival rate
was higher in the PPX arm (15%) compared with the control
arm (10%). With the Rothmann method18 for determination
of noninferiority, PPX retained at least 50% of the efficacy of
the control arm (p  0.039).
The results of the Cox modeling process suggested that,
holding all other factors constant, significant predictors of
survival were the presence of extrathoracic metastases, ex-
cluding brain metastases (HR  1.61; p  0.001); lactate
dehydrogenase (HR  1.46; p  0.003); FACT-LCS score
(HR  1.50; p  0.001); and tobacco use (HR  1.78; p 
0.001). The treatment arm did not impact survival (HR 
0.95; p  0.686).
Prespecified analyses of survival by stratification fac-
tors including gender, geographic location, disease stage, and
history of brain metastases were performed (Table 4). Sur-
vival was similar between treatment groups in all subgroups;
however, there was a nonsignificant trend toward improved
survival in women in the PPX arm compared with women in
the comparator arm (10 versus 7 months, respectively; HR 
0.65; p  0.069). The number of patients who received
poststudy chemotherapy was similar between treatment arms
(36% versus 39%). No major differences were noted in the
types of therapy administered between the 2 arms. Less than
5% of patients in either arm received subsequent therapy with
epidermal growth factor receptor antagonists. Survival was
similar between the study arms in patients who did not
receive poststudy chemotherapy (5.8 versus 5.9 months;
HR  1.13; p  0.390).
Assessment times were 2 weeks longer for gemcitabine
than for vinorelbine or PPX, making direct comparison prob-
lematic. However, TTP was similar between treatment groups
(87 days for PPX versus 107 days for the comparator; HR 
1.08; p  0.480). Response rate (11% for PPX versus 15%
TABLE 2. Demographic and Baseline Characteristics
PPX (175 mg/m2)
(n  191)
Gemcitabine or
Vinorelbine
(n  190)
Gender (%)
Male 142 (74.3) 134 (70.5)
Female 49 (25.7) 56 (29.5)
Race (%)
White 170 (89.0) 170 (89.5)
Black 3 (1.6) 9 (4.7)
Asian 2 (1.0) 1 (0.5)
Hispanic 13 (6.8) 7 (3.7)
Other 3 (1.6) 3 (1.6)
Age at randomization
Mean (SD) 61.4 (9.85) 62.8 (10.29)
Median (range) 61.0 (36–86) 64.0 (30–90)
Geographic site (%)
United States 16 (8.4) 24 (12.6)
Western Europe and Canada 16 (8.4) 25 (13.2)
Other 159 (83.2) 141 (74.2)
Histology (%)
Squamous 86 (45) 102 (54)
Adenocarcinoma 70 (37) 61 (32)
Bronchoalveolar 5 (3) 1 (1)
Other 30 (16) 26 (14)
Stage at randomization (%)
IIIa 1 (1) 2 (1)
IIIb 60 (31) 59 (31)
IV 130 (68) 129 (68)
History of brain metastases 3 (8) 1 (2)
Extrathoracic metastases 75 (39) 84 (44)
Prior radiotherapy 30 (16) 39 (21)
5% weight loss 60 (31) 66 (35)
Never smoked 36 (19) 34 (18)
PPX indicates paclitaxel poliglumex; SD, standard deviation.
TABLE 3. Efficacy Results in the Intent-to-Treat Population
PPX (n  191)
Gemcitabine or
Vinorelbine
(n  190)
Survival
Median, d 220 198
95% CI 198, 263 173, 220
Hazard ratio (95% CI); log-rank p 0.95 (0.76, 1.20); 0.686
1-yr survival rate, % 26 26
95% CI 20, 33 19, 32
2-yr survival rate, % 15 10
95% CI 5, 25 3, 16
Time to progression
Median, d 87 107
95% CI 81, 122 87, 112
Hazard ratio (95% CI); log-rank p 1.08 (0.87, 1.33); 0.480
Disease control, % (95% CI) 52 (45, 59) 59 (52, 67)
Response rate (patients with
measurable disease only)
No. of patients 180 179
PR  CR, % (95% CI) 11 (6, 16) 15 (10, 21)
Confirmed PR  CR, % (95% CI) 5 (2, 9) 7 (4, 12)
PPX indicates paclitaxel poliglumex; CI, confidence intervals; PR, partial response;
CR, complete response.
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for the comparator) and disease control (52% for PPX versus
59% for the comparator) were also similar.
Supportive Care
In the PPX arm compared with the comparator arm,
there was a decreased use of red blood cell transfusions (p 
0.001), erythropoietin (p  0.014), myeloid growth factors
(p  0.032), and new narcotic analgesics (p  0.034).
Quality of Life
FACT-LCS evaluations were completed by 178 pa-
tients on the PPX arm and 165 patients on the comparator
arm. No significant difference in the FACT-LCS scores was
seen.
Toxicity
Adverse events are summarized in Table 5. Lower
rates of hematologic (p  0.001) and gastrointestinal (p 
0.004) adverse events were observed in the PPX arm.
Neuropathy occurred more frequently in the PPX arm
compared with control (30% versus 5%, (p  0.001).
Grade 3 neuropathy occurred in 4% of patients in the PPX
arm; however, no grade 4 neuropathy occurred. Alopecia
occurred less frequently in the PPX arm compared with the
comparator arm (2% versus 9%, respectively, p  0.085),
as did fatigue (42% versus 55%, p  0.055), asthenia (11%
versus 16%, p  0.169), and weight loss (7% versus 12%,
p  0.121). There were no treatment-related deaths in
either arm. The number of patients who withdrew due to
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FIGURE 1. Overall survival using Kaplan-
Meier estimation: Paclitaxel poliglumex versus
gemcitabine or vinorelbine.
TABLE 4. Subgroup Analysis of Overall Survival
Subgroup
PPX (n  191)
Gemcitabine
or Vinorelbine
(n  190)
Hazard Ratio p*n
Median OS, d
(95% CI) n
Median OS, d
(95% CI)
Overall 191 220 (198, 263) 190 198 (173, 220) 0.95 (0.76, 1.20) 0.686
Gender
Male 142 208 (168, 234) 134 190 (165, 220) 1.08 (0.82, 1.41) 0.579
Female 49 312 (216, 408) 56 209 (169, 271) 0.65 (0.40, 1.04) 0.069
Geographic location
United States 16 203 (127, 373) 24 163 (109, 234) 0.70 (0.34, 1.43) 0.324
Western Europe and Canada 16 164 (96, 271) 25 155 (132, 306) 1.29 (0.65, 2.57) 0.464
Other 159 228 (201, 271) 141 201 (177, 255) 0.99 (0.76, 1.29) 0.946
History of brain metastases
Yes 6 294 (221, 373) 6 187 (90, 206) 0.17 (0.03, 0.88) 0.020
No 185 217 (197, 259) 184 198 (174, 228) 0.98 (0.77, 1.24) 0.841
Disease stage at randomization
IV 130 216 (168, 244) 129 177 (150, 206) 0.89 (0.67, 1.17) 0.392
Other 61 266 (189, 285) 61 247 (193, 334) 1.10 (0.72, 1.68) 0.660
*Log-rank test.
PPX indicates paclitaxel poliglumex; OS, overall survival; CI, confidence intervals.
O’Brien et al. Journal of Thoracic Oncology • Volume 3, Number 7, July 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer732
adverse events was similar between treatment arms, and
most were events resulting from disease progression. Ad-
verse events resulted more frequently in dose reduction in
the comparator arm (13%) compared with the PPX arm
(4%). The dose reductions most frequently resulted from
hematologic events in the comparator arm. Neuropathy
resulted in dose reduction in 4 (2%) patients in the PPX
arm; neuropathy did not occur in the comparator arm.
DISCUSSION
Despite patients having PS 2 being relatively common
in clinical situations, remarkably few studies have been
dedicated to this topic (Table 1). This is the largest series of
patients with PS 2 in a clinical trial. In the present study,
PPX, an active macromolecular paclitaxel conjugate, was
compared with gemcitabine or vinorelbine in a randomized,
controlled international study in PS 2 chemotherapy-naive
patients with advanced NSCLC. The accrual period was 30
months, during which a total of 487 patients were enrolled,
demonstrating that such studies are feasible. The primary
objective was to compare survival with secondary objectives
of other efficacy measures and tolerability. After a dose
reduction of PPX to 175 mg/m2, 190 patients were accrued at
this dose and 191 to gemcitabine or vinorelbine, and these
patients are analyzed in this report. Median survival was
similar for the 2 study arms (7.3 months for the PPX arm
versus 6.6 months for the control arm). This survival duration
is considerably longer than prior reports for single-agent
therapy in PS 2 patients (Table 1). The longer survival
observed in this study was observed across all geographic
regions. The demographics of the population under study
were similar to those reported in other PS 2 trials with respect
to age, percent weight loss, stage, and presence of extratho-
racic metastases. In a Cox multivariate linear regression
model, important negative survival factors were the presence
of extrathoracic metastases, a FACT-LCS score 18, lactate
dehydrogenase 200 U/L, and a history of smoking. Treat-
ment arm was not significant. Response rates were similar
between the 2 arms (11% for the PPX arm versus 15% for the
comparator arm), and TTP was 20 days longer in the gem-
citabine/vinorelbine arm (HR  1.08; p  0.480).
The analysis plan specified that survival would be
examined by each of the stratification factors. When survival
was analyzed by geography, stage, or presence of brain
metastases, there were no apparent effects on survival. How-
ever, there was a strong nonsignificant trend toward improved
survival for women treated with PPX (HR  0.65; p 
0.069). Recent preclinical data indicate that PPX efficacy in
human tumor xenograft models expressing estrogen receptor
 is enhanced by estradiol.
Both PPX and gemcitabine/vinorelbine were well tol-
erated with relatively few grade 3 nonhematopoietic toxici-
ties. The median number of cycles administered was 4.0 and
3.5 for the PPX and comparator arms, respectively. Grade 3
neutropenia and anemia occurred more frequently in the
gemcitabine/vinorelbine arm and was associated with a
higher red blood cell transfusion requirement and use of more
growth factor support. Neuropathy was more common in the
PPX arm, but only 4% of patients had grade 3 despite
administration of 6 cycles of therapy to 38% of the patients.
CONCLUSIONS
Patients in both arms of this study had comparable
survival rates, and both treatments represent reasonable al-
ternatives for PS 2 patients. Both therapies were well toler-
ated with no drug-associated deaths and relatively few non-
TABLE 5. No. (%) of Patients with Select Adverse Events
Adverse Event
Toxicity
PPX (175 mg/m2)
(n  190)
Gemcitabine or
Vinorelbine (n  187)
p*All Grade 3/4 All Grade 3/4
Anemia NOS 27 (14%) 5 (3%) 68 (36%) 17 (9%) 0.001
Neutropenia 11 (6%) 4 (2%) 27 (14%) 15 (8%) 0.006
Leukopenia NOS 14 (7%) 4 (2%) 20 (11%) 5 (3%) 0.285
Febrile neutropenia 2 (1%) 2 (1%) 1 (1%) 1 (1%) 1.000
Anorexia 27 (14%) 4 (2%) 27 (14%) 2 (1%) 1.000
Dehydration 3 (2%) 2 (1%) 8 (4%) 3 (2%) 0.138
Neuropathy NOS 57 (30%) 8 (4%) 10 (5%) 0
Dyspnea NOS 41 (22%) 25 (13%) 56 (30%) 32 (17%) 0.077
Nausea 37 (19%) 0 54 (29%) 2 (1%) 0.041
Vomiting NOS 16 (8%) 0 32 (17%) 3 (2%) 0.013
Diarrhea NOS 15 (8%) 2 (1%) 12 (6%) 0 0.691
Arthralgia 10 (5%) 1 (1%) 9 (5%) 3 (2%) 1.000
Fatigue 79 (42%) 19 (10%) 103 (55%) 16 (9%) 0.055
Asthenia 20 (11%) 13 (7%) 29 (16%) 14 (7%) 0.169
Weight decrease 14 (7%) 1 (1%) 23 (12%) 2 (1%) 0.121
Alopecia 3 (2%) NA 9 (5%) NA 0.085
*p value based on Fisher exact test for difference in all adverse events between treatment groups.
PPX indicates paclitaxel poliglumex; NOS, not otherwise specified; NA, not applicable.
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hematopoietic 3/4 toxicities. Patients on PPX required fewer
red blood cell transfusions, hematopoietic growth factors, and
opioid analgesics than patients receiving gemcitabine or
vinorelbine and because the agent was administered once
every 3 weeks, they required substantially fewer clinic visits
than those patients receiving either gemcitabine or vinorel-
bine. The intriguing exploratory finding that women may
have an improved outcome with PPX will be evaluated in a
phase III study.
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